Health

Samsung Biologics reports fourth quarter and fiscal year 2025 financial results

* Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion * Maintained momentum through consistent operational performance and robust client demand * Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale INC...

2026-01-21 15:20 5842

HistoIndex Partners with Houston Research Institute to Expand Advanced MASH Diagnostic Services

SINGAPORE, Jan. 21, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is a leading research institute focused on conducting clinical trials in hepatology a...

2026-01-21 11:00 4703

CLEARLAB CONTACT LENSES AND LENS CARE PRODUCTS RECEIVE COMBINED MDSAP, ISO13485 AND EU MDR CERTIFICATION FROM DNV

Parallel audit streamlines certification and speeds up access to global markets SINGAPORE, Jan. 21, 2026 /PRNewswire/ -- DNV, the independent global assurance and risk management provider, has certified contact lenses and multi-purpose lens care solutions from Clearlab in accordance with the Medi...

2026-01-21 10:00 4425

HD Partners with Pacific Prime to Pioneer AI-Native Healthcare Navigation and Hybrid Access Models in Emerging Southeast Asia

* Strategic partnership expands access to hybrid healthcare models through AI-driven navigation, connecting Pacific Prime clients to HDmall, HDcare, and Jib AI across Southeast Asia. * HD aims to become the AI-native healthcare front door for emerging Southeast Asia, while guiding patients to...

2026-01-21 09:00 6407

Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.

IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ -- Gene Solutions , a global biotechnology company, andPangea Laboratory

2026-01-21 09:00 5590

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insi...

2026-01-21 08:15 6374

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

* Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases * Enhances strong global regulatory momentum, ...

2026-01-21 06:00 5213

Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand

DEERFIELD, Ill., Jan. 21, 2026 /PRNewswire/ -- Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched earlier, this Summer, across Australia and New Zealand. Since its introduction, the product has been met w...

2026-01-21 03:00 3747

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broaden...

2026-01-21 01:55 4286

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughput Kinase Inhibitor Screening

HOUSTON, Jan. 20, 2026 /PRNewswire/ -- Sino Biological, Inc. is proud to announce the launch of its innovativeSwiftFluo® TR-FRET Kinase Assay Kits , a ready-to-use, high-performance solution designed to accelerate kinase...

2026-01-20 23:00 4623

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

BEIJING, Jan. 20, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics f...

2026-01-20 20:00 7139

SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceuticalmanufacturing and hospital workflows TAICHUNG, Jan. 20, 2026 /PRNewswire/ -- SAG today announced LiquidMate O, its debut UHF RFID label and a category-defining advancement in pharmaceutical RFID and ite...

2026-01-20 20:00 4403

4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging

Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product,strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more LOS ANGELES and MELBOURNE, Australia, Jan. 20, 2026 /PRNewswire/ -- 4DMedical, the lead...

2026-01-20 19:00 6605

GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation

SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- On January 9th, GENEIII reaffirmed its global leadership in ergothioneine production and scientific validation at the "Research Without Borders • Tracing the Source with GENEIII" Global Evidence-Based Journey. GENEIII joined forces with core partners to v...

2026-01-20 18:09 4344

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent t...

2026-01-20 17:00 4805

Merck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation

Strategic collaboration establishes a framework to integrate automated experimentation and advanced chemistry workflows to accelerate research and discovery in Life Science and Electronics SINGAPORE and SHANGHAI, Jan. 20, 2026 /PRNewswire/ -- Merck, a leading science and technology company, and ...

2026-01-20 16:17 5586

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteog...

2026-01-20 15:55 5646

Infinitus Recognised as a Top Employer in China for 2026 for the Sixth Consecutive Year

GUANGZHOU, China, Jan. 20, 2026 /PRNewswire/ -- Infinitus, a leader in the health and wellness industry, is pleased to announce that it has been recognised as a"Top Employer in China for 2026" by the Top Employers Institute, marking thesixth consecutive year the company has earned this distinguis...

2026-01-20 15:51 4539

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights * Full-year (FY) 2...

2026-01-20 15:16 9033

cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments

SYDNEY, Jan. 20, 2026 /PRNewswire/ -- Cerebral Palsy Alliance, The University of Sydney, and CSIRO, Australia's national science agency, have commissioned Miroma Project Factory to deliver a groundbreaking mobile app that helps people with cerebral palsy (CP), their carers, and clinicians underst...

2026-01-20 13:46 4020
1 ... 15161718192021 ... 870

Week's Top Stories